![Page 1: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/1.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients
aged 3 to <6 years: Week 48 analysis of the ARIEL trial
Avy Violari,1 Rosa Bologna,2 Nagalingeswaran Kumarasamy,3 Jose Henrique Pilotto,4 Annemie Hendrickx,5 Thomas N Kakuda,6 Erkki Lathouwers,5 Magda Opsomer,5 Tom Van de Casteele5 and
Frank L Tomaka6
1Chris Hani Baragwanath Hospital, Johannesburg, South Africa; 2Helios Salud, Buenos Aires, Argentina; 3YRGCARE Medical Centre, VHS, Chennai, India; 4Hospital Geral De Nova Iguacu,
Rio De Janeiro, Brazil; 5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Janssen Research & Development LLC, Titusville, NJ, USA
![Page 2: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/2.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
Background
1. Violari A, et al. 18th CROI 2011. Abstract 713DRV/r = darunavir/ritonavir*TMC114-TiDP29-C228; NCT00919854ARIEL=dArunavir in tReatment experIenced pEdiatric popuLation
• DRV/r is approved for HIV-1-infected children and adolescents aged 3 to <18 years
• The primary 24 week analysis of ARIEL1,* led to the approval of DRV/r for treatment-experienced children aged 3 to <6 years weighing at least 10kg
• 48-week safety and efficacy outcomes from ARIEL are reported
![Page 3: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/3.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL: study design and objectives
• Phase II, open-label trial conducted in five countries*
• Primary objective– Assess pharmacokinetics, short-term safety and efficacy to support dose
recommendations of DRV/r by bodyweight in children
• Dosing– Initial dose of DRV/r 20/3mg/kg bid– DRV 100mg/mL oral suspension and ritonavir 80mg/mL solution
• After Week 2 analysis and Data Safety Monitoring Board recommendations– 25/3mg/kg bid for patients weighing 10 to <15kg– 375/50mg bid fixed for patients weighing 15 to <20kg
1. Johnson VA, et al. Top HIV Med 2009;17:138–45
• Treatment-experienced children aged 3 to <6 years
• Bodyweight 10 to <20kg• HIV-1 RNA >1,000 copies/mL• <3 DRV RAMs1 at screening• On HAART for ≥12 weeks
DRV/r oral suspension + OBR† (N=27)
Primary analysis at Week 24
†Investigator-selected OBR of ≥2 allowed antiretrovirals
Week 48
HAART = highly active antiretroviral therapyOBR = optimised background regimenRAM = resistance-associated mutation*Argentina, Brazil, India, Kenya, and South Africa
![Page 4: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/4.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL: baseline demographics and disease characteristics
N=21*DemographicsMale, n (%) 10 (47.6)Median (range) age, years 4.4 (3–6)Race, n (%)
White 6 (29)Black or African-American 12 (57)Asian 1 (5)Multiple‡ 2 (10)
Baseline virologic and immunologic parametersMean (SE) BL log10 HIV-1 RNA 4.34 (0.18)Median (range) CD4+ cell count, cells/mm3 927 (209–2,429)Median (range) CD4+ cell, percentage 27.7 (15.6–51.1)Median (range) number of baseline IAS-USA1 RAMsPrimary PI mutations 0 (0–3)Secondary PI RAMs 4 (1–14)DRV RAMs 0 (0–2)NRTI RAMs§ 1 (0–5)NNRTI RAMs 1 (0–4)Median (range) fold change in EC50 for DRV 0.55 (0.2–2.3)
SE = standard error; EC50 = 50% effective concentrationPI = protease inhibitor; BL = baseline
*42 patients screened, 27 enrolled and treated with DRV/r + OBR and 21 patients (from 10 sites) included in the Week 48 analysis; ‡Black or African American/White; §17/18 patients with NRTI RAMs harboured the M184V RAM
1. Johnson VA, et al. Top HIV Med 2010;18:156–63
![Page 5: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/5.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 analysis:previously used antiretrovirals
N=21Number of previously used antiretrovirals n (%)PIs
0 5 (24)1 12 (57)≥2 4 (19)
NRTIs2 17 (81)≥3 4 (19)
NNRTIs≥ 1 13 (62)
Type of antiretrovirals n (%)Lopinavir/ritonavir 16 (76)Lamivudine 21 (100)Stavudine 12 (57)Nevirapine 10 (48)
![Page 6: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/6.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 analysis:antiretrovirals in the OBR
N=21Number of NRTIs* n (%)
2 19 (90)
3 2 (10)
Type of NRTIs n (%)
Lamivudine 13 (62)
Zidovudine 13 (62)
Abacavir 8 (38)
Stavudine 8 (38)
Didanosine 1 (5)
Tenofovir disoproxil fumarate 1 (5)
*Of the patients with antiretroviral susceptibility (Antivirogram®) data on Day 7 (N=17), 11 patients (65%) had ≥2 susceptible NRTIs in the underlying OBR. None of the patients had an NNRTI in the underlying OBR
![Page 7: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/7.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 overall safety analysis
N=21
Mean exposure, weeks 47.9
AE incidence n (%)
≥1 AE (regardless of cause or severity) 20 (95)
≥1 AE* at least possibly related to DRV 1 (5)
Total discontinuations‡ 1 (5)
≥1 AE leading to permanent discontinuation 1 (5)
≥1 grade 3 or 4 AE§ 2 (10)
≥1 AE ≥ grade 2 at least possibly related to treatment 0
Deaths 0
AE = adverse event; ECG = electrocardiogram
*ECG QT prolonged (QTcF was normal); ‡Occurred ≤Week 24 and was due to grade 2 vomiting, considered very likely related to ritonavir; §Two patients had grade 4 AEs (stenosing tenosynovitis and asthmatic crisis), both considered serious but not treatment related
![Page 8: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/8.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
Rhinorrhea
Rhinitis
Rash
Pyrexia
Nasal congestion
Impetigo
Vomiting
Nasopharyngitis
Tinea capitis
Diarrhea
Cough
Upper respiratory tract infection
0 10 20 30 40 50 60 70 80 90 100
ARIEL Week 48 analysis: most commonly reported AEs*
19% (n=4)
14% (n=3)
29% (n=6)
24% (n=5)
Percentage of patients (N=21)
*Occurring in ≥3 patients, regardless of causality or severity and excluding laboratory abnormalities reported as AEs
![Page 9: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/9.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 laboratory safety analysis
• There were no clinically relevant changes from BL for any laboratory parameter
• All laboratory abnormalities were grade 1 or 2 in severity, with the exception of grade 3 neutropenia reported in one patient, which was present since BL and not considered treatment related
![Page 10: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/10.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 analysis: growth parameters
• Mean age-adjusted z-scores at BL showed patients were below normal population values– z-scores remained stable throughout the trial
• The mean increase from BL to Week 48 for height was 5cm, weight 1.7kg and BMI 0.1kg/m2
BMI = body mass index*Wilcoxon’s matched pairs signed ranks test
![Page 11: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/11.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
0 8 16 24 32 40 480
20
40
60
80
100
HIV-1 RNA <400 copies/mL
HIV-1 RNA <50 copies/mL
ARIEL: proportion of patients achieving virologic response over 48 weeks of
treatment (ITT-TLOVR; N=21)V
iro
log
ic r
esp
on
se (
±SE
) (%
)
Time (weeks)
ITT-TLOVR = intent-to-treat/time-to-loss of virologic response
57.1%
81.0%85.7%81.0%
![Page 12: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/12.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL: proportion of patients achieving virologic response at Week 48 (N=21)
Series10
20
40
60
80
100
81.0
71.4
85.790.5
Vir
olo
gic
res
po
nse
(%
)
HIV-1 RNA <50 copies/mL (ITT-TLOVR)
HIV-1 RNA <50 copies/mL (FDA Snapshot)
HIV-1 RNA <400 copies/mL
(ITT-TLOVR)
≥1 log10 drop in HIV-1 RNA
(ITT-TLOVR)
FDA = Food and Drug Administration
![Page 13: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/13.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
0 8 16 24 32 40 48-40
0
40
80
120
160
200
240
280
109
187
ARIEL: change in CD4+ cell count (N=21)
• Mean (SE) change in CD4+ % from BL to Week 48: 4.0 (1.3)%
Mea
n (
±SE
) ch
ang
e in
C
D4+
cel
l co
un
t (N
C=
F*)
, ce
lls/m
m3
NC=F = non-completer=failure *Missing values were imputed as a change of 0 (using the NC=F analysis; The mean change in absolute CD4+ cell count from BL (cells/mm3) is shown at each timepoint
Time (weeks)
![Page 14: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/14.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 resistance analysis
• Two patients with BL DRV RAMs (L33F/L + L76V [n=1] and L76V [n=1]) had HIV-1 RNA <50 copies/mL at Weeks 24 and 48
• There were three (14%) VFs at Week 48 (two never suppressed; one rebounder)
• Two VFs with paired BL/endpoint genotypes– neither developed IAS-USA1 PI or NRTI RAMs
– both remained susceptible to DRV and NRTIs in the OBR
1. Johnson VA, et al. Top HIV Med 2010;18:156–63
VFs = virologic failures: rebounders or never achieved HIV-1 RNA <50 copies/mL using a TLOVR non-VF censored analysisResponses after discontinuation were not imputed for patients who discontinued for reasons other than VF
![Page 15: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/15.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
ARIEL Week 48 safety and efficacy analysis: summary
• Over 48 weeks, treatment-experienced, HIV-1-infected children aged 3 to <6 years receiving DRV/r and an OBR showed a high virologic response and a favorable safety profile – 81% of patients had HIV-1 RNA <50 copies/mL (ITT-TLOVR)– no new safety concerns were reported compared with the known
safety profile of DRV/r
• No development of resistance (development of RAMs or loss of susceptibility to DRV or NRTIs in the OBR) was observed in VFs
• Doses of DRV/r have been established and recommended in treatment-experienced, HIV-1-infected patients aged 3 to <6 years1
1. Kakuda TN, et al. IWCPHIV 2013; Abstract O_13
![Page 16: Violari A, et al. 7th IAS 2013. Abstract MOAB0102 Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to](https://reader036.vdocument.in/reader036/viewer/2022072013/56649e4b5503460f94b3f083/html5/thumbnails/16.jpg)
Violari A, et al. 7th IAS 2013. Abstract MOAB0102
Acknowledgements
• We would like to express gratitude to
– the patients who participated in this trial and their families, the investigators and the trial centre staff
– Janssen R&D team members, in particular David Anderson, Bryan Baugh and Eric Wong for their input into this presentation
• This trial was sponsored by Janssen R&D Ireland
• Medical writing support was provided by Ian Woolveridge of Gardiner-Caldwell Communications, Macclesfield, UK; this support was funded by Janssen
• The authors have the following conflicts of interest to declare: AV is a member of the rilpivirine paediatric Data Safety Monitoring Board. RB, NK and JHP declare they have no conflicts of interest. AH, TNK, EL, MO, TVdC and FLT are all full-time employees of Janssen